Bedinvetmab

Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF) . Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs[1][2].

Product Specifications

CAS Number

[2171034-69-6]

Product Name Alternative

ZTS-00508841

UNSPSC

12352203

Target

Trk Receptor

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bedinvetmab.html

Purity

99.80

Solubility

H2O

Smiles

[Bedinvetmab]

Molecular Weight

(145.34 kDa)

References & Citations

[1]Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48 (6) :943-955.|[2]Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733.